form8_kjan262009.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported) January 26,
2009
Progenics
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-23143
|
|
13-3379479
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
|
|
|
|
|
777 Old Saw Mill River Road, Tarrytown, New
York
|
|
10591
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant's telephone number,
including area code (914)
789-2800
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
o Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
8.01. Other Events.
Wyeth
Pharmaceuticals, a division of Wyeth (NYSE: WYE), with which Progenics
collaborates in the development and commercialization of RELISTOR®, has
informed Progenics that global net sales of RELISTOR for the fourth quarter of
2008 were $1.5 million, as compared to $0.8 million in the third quarter of
2008. Wyeth began full promotion of RELISTOR in mid-August, under a
program that included sales detailing, the offering of early experience trial
kits and company-directed educational programs. Global net sales for 2008,
which commenced in June, totaled $4.4 million.
RELISTOR
is the first drug in a novel class for a completely new therapeutic use –
opioid-induced constipation. The approved indication for RELISTOR
addresses the needs of individuals with advanced illness receiving palliative
care. Ongoing clinical studies have the goal of expanding the use of
RELISTOR in other patient settings.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
PROGENICS
PHARMACEUTICALS, INC.
By: /s/ ROBERT A.
MCKINNEY
Robert A.
McKinney
Chief Financial Officer, Senior
Vice President,
Finance & Operations and
Treasurer
Date: January
26, 2009